Scott Friedman, MD
Ophthalmology · Lakeland, FLNPI 1497842314
Payments from drug & device makers
Across 666 payments — averaging $2557.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$712K
- Bayer$266K
- Boehringer Ingelheim International GmbH$208K
- Amgen$166K
- Ocular Therapeutix, Inc.$152K
- Roche TCRC, Inc.$85K
- plus $114K from 29 others
Across 11 payments — averaging $490.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 294 | $711,769 |
| Bayer | 14 | $266,454 |
| Boehringer Ingelheim International GmbH | 109 | $208,297 |
| Amgen(2 entities) | 16 | $166,414 |
| Ocular Therapeutix, Inc. | 17 | $152,215 |
| Roche TCRC, Inc. | 10 | $84,653 |
| Eyepoint US, Inc. | 6 | $74,778 |
| AbbVie(2 entities) | 25 | $16,060 |
| Genentech USA, Inc. | 59 | $7,154 |
| Boehringer Ingelheim | 3 | $4,653 |
| Apellis Pharmaceuticals, Inc. | 18 | $3,091 |
| Boehringer Ingelheim Finland Ky | 15 | $2,627 |
| Regeneron Healthcare Solutions, Inc. | 25 | $1,692 |
| Kowa Research Institute, Inc. | 1 | $500 |
| Harrow Eye, LLC | 7 | $417 |
| Alimera Sciences, Inc. | 5 | $297 |
| Sun Pharmaceutical Industries Inc. | 3 | $270 |
| Sight Sciences, Inc. | 2 | $249 |
| Alcon | 2 | $242 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $242 |
| Astellas Pharma US Inc | 5 | $176 |
| ANI Pharmaceuticals, Inc. | 3 | $164 |
| Novartis | 3 | $153 |
| NEW World Medical,inc. | 1 | $142 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $129 |
| Dompe US, Inc. | 1 | $121 |
| Bausch & Lomb Americas Inc. | 5 | $107 |
| Ivantis, Inc | 1 | $101 |
| Coherus Oncology, Inc. | 3 | $96 |
| Pfizer | 2 | $35 |
| Biogen | 2 | $33 |
| Glaukos Corporation | 1 | $29 |
| Rxsight Inc | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
| Mimedx Group, Inc. | 1 | $15 |
How this compares
$1,703,417 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Lakeland
- Jay MulaneyLakeland$913K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.